Melanie Rolli
Chief Executive Officer chez Helsinn Healthcare SA
Profil
Melanie Rolli is currently the Group Chief Executive Officer at Helsinn Healthcare SA. Prior to her current position, she served as the Chief Executive Officer at Aelix Therapeutics SL.
She also held the role of Independent Director at ERYTech Pharma SA from 2020 to 2023.
Before that, Dr. Rolli was the Chief Operating Officer at PIQUR Therapeutics AG from 2018 to 2020.
Dr. Rolli obtained her doctorate degree from Ruprecht-Karls-Universität Heidelberg in 1999.
Postes actifs de Melanie Rolli
| Sociétés | Poste | Début |
|---|---|---|
Helsinn Healthcare SA
 Helsinn Healthcare SA Pharmaceuticals: MajorHealth Technology Helsinn Healthcare SA develops and provides licenses for drugs. The firm offers services to oncology, cancer supportive care, pain and inflammation, gastrointestinal fields. The company was founded by Gabriele Braglia in 1976 and is headquartered in Pazzallo, Switzerland. | Chief Executive Officer | 01/01/2023 |
Anciens postes connus de Melanie Rolli
| Sociétés | Poste | Fin |
|---|---|---|
ERYTech Pharma SA
 ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France. | Director/Board Member | 23/06/2023 |
Aelix Therapeutics SL
 Aelix Therapeutics SL BiotechnologyHealth Technology Aelix Therapeutics SL researches and develops therapies for HIV. It develops therapeutic vaccines and immunotherapies to treat HIV infection. The firm is a spin-off of HIVACAT, the Catalan project for the development of effective vaccines against HIV. The company was founded by Christian Brander, Bonaventura Clotet, Josep Maria Gatell and Jordi Naval is headquartered in Barcelona, Spain. | Chief Executive Officer | - |
PIQUR Therapeutics AG
 PIQUR Therapeutics AG Pharmaceuticals: OtherHealth Technology PIQUR Therapeutics AG engages in development of anti-cancer drugs based on the inhibition. Its products include PQR309, PQR620 and PQR5xx. The company was founded by Bernd Giese, Vladimir Cmiljanovic, Andreas Emmenegger, Ralf Rosenow and Matthias Wymann in August 2011 and is headquartered in Basel, Switzerland. | Chief Executive Officer | - |
Formation de Melanie Rolli
| Ruprecht-Karls-Universität Heidelberg | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Helsinn Healthcare SA
Helsinn Healthcare SA Pharmaceuticals: MajorHealth Technology Helsinn Healthcare SA develops and provides licenses for drugs. The firm offers services to oncology, cancer supportive care, pain and inflammation, gastrointestinal fields. The company was founded by Gabriele Braglia in 1976 and is headquartered in Pazzallo, Switzerland. | Health Technology |
ERYTech Pharma SA
ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France. | Health Technology |
PIQUR Therapeutics AG
PIQUR Therapeutics AG Pharmaceuticals: OtherHealth Technology PIQUR Therapeutics AG engages in development of anti-cancer drugs based on the inhibition. Its products include PQR309, PQR620 and PQR5xx. The company was founded by Bernd Giese, Vladimir Cmiljanovic, Andreas Emmenegger, Ralf Rosenow and Matthias Wymann in August 2011 and is headquartered in Basel, Switzerland. | Health Technology |
Aelix Therapeutics SL
Aelix Therapeutics SL BiotechnologyHealth Technology Aelix Therapeutics SL researches and develops therapies for HIV. It develops therapeutic vaccines and immunotherapies to treat HIV infection. The firm is a spin-off of HIVACAT, the Catalan project for the development of effective vaccines against HIV. The company was founded by Christian Brander, Bonaventura Clotet, Josep Maria Gatell and Jordi Naval is headquartered in Barcelona, Spain. | Health Technology |
